IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4508
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$39M
Chee Kong Choo
We are a pre-clinical biopharmaceutical company focused on harnessing our licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. As of the date of this Prospectus, the registrant is a public company limited by shares known as CytoMed Therapeutics Limited. On January 19, 2023, the registrant converted from a private company limited by shares incorporated in Singapore, known as CytoMed Therapeutics Pte. Ltd. to a public company limited by shares pursuant to the provisions of the Singapore Companies Act. Our principal executive office in Singapore is located at 1 Commonwealth Lane, #08-22, Singapore.
Headcount
—
HQ Base
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$GDTC CytoMed Therapeutics Ltd | 30 | 15 | 32 | 9 | - | - | -112.5% | -100.2% | -347.1% | -687.1% | -687.1% | 171.9% | 0.0% | 5.0x | $39M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
CytoMed Therapeutics Ltd (GDTC) receives a "Avoid" rating with a composite score of 30.3/100. It ranks #4508 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Chee Kong Choo
Chief Executive Officer
15
50
39
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for GDTC
Pending Verification
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for GDTC.
View All RatingsMaterial decline in asset turnover efficiency detected
ROE proxy -112.5% (sector -2.5%)
GM -347% vs sector 43%, OM -687% vs sector 1%
Capital turnover N/A, R&D intensity 520.2%
Rev growth 172%, 3yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags CytoMed Therapeutics Ltd with an Avoid rating, assigning a composite score of 30.3/100 and 1 out of 5 stars. Ranked #4508 of 7,333 stocks, GDTC falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CytoMed Therapeutics Ltd registers a weak quality score of just 15/100, indicating significant profitability challenges. The company reports a return on equity of -112.5% (sector avg: -2.5%), gross margins of -347.1% (sector avg: 42.5%), net margins of -687.1% (sector avg: -0.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 32/100, GDTC appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 1.88x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
With an investment score of 50/100, GDTC exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 171.9% vs. a sector average of 5.9% and a return on assets of -100.2% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
CytoMed Therapeutics Ltd is experiencing notably weak momentum with a score of just 9/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 171.9% year-over-year, while a beta of 0.91 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
GDTC's stability score of 39/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.91 and a debt-to-equity ratio of 5.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
GDTC's short interest factor score of 88/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 5.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $39M, CytoMed Therapeutics Ltd benefits from the generally lower volatility and deeper liquidity associated with its size class.
CytoMed Therapeutics Ltd is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4508 of 7,333 overall (39th percentile). Key comparisons include ROE of -112.5% trailing the -2.5% sector median and operating margins of -687.1% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While GDTC currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (9) would have the largest impact on the composite score.
ROE 4437% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 917% BELOW SECTOR MEDIAN
Op. Margin 53361% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate CytoMed Therapeutics Ltd (GDTC) as Avoid with a composite score of 30.3/100 at a current price of $1.02. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in investment (50th percentile) and stability (39th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (9th percentile) and quality (15th percentile) tempers our overall conviction. We assign a No Moat rating (28/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
CytoMed Therapeutics Ltd holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.3/100 places it at rank #4508 in our full 7,333-stock universe. At $39M in market capitalization, CytoMed Therapeutics Ltd is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 172%, though momentum at the 9th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of -347% (-389.6pp vs sector) narrow to operating margins of -687% (-688.4pp vs sector) and net margins of -687.1%, yielding a gross-to-net conversion rate of N/A%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $1.02, CytoMed Therapeutics Ltd is trading at a premium to fundamental value. Our value factor score of 32/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 1.9x, P/S of 11.5x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Revenue growth of 172% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (5% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 30.3/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -687.1% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (9th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a High uncertainty rating to CytoMed Therapeutics Ltd. Key risk factors include current negative profitability (net margin -687.1%), below-average price stability (39th percentile), weak quality scores (15th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -687.1%); below-average price stability (39th percentile); weak quality scores (15th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 39th percentile and quality factor at the 15th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (5% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate CytoMed Therapeutics Ltd's capital allocation as Poor. Key concerns include low returns on equity (-112.5%), negative profitability, weak asset returns (ROA -100.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — CytoMed Therapeutics Ltd significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, CytoMed Therapeutics Ltd receives a Avoid rating with a composite score of 30.3/100 (rank #4508 of 7,333). Our quantitative framework assigns a No Moat (28/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 29/100.
Our analysis does not support a constructive view on CytoMed Therapeutics Ltd at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign CytoMed Therapeutics Ltd a meaningful economic moat, scoring 28/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 10.7/20.
The strongest moat sources are growth durability (10.7/20) and reinvestment efficiency (7/20). Rev growth 172%, 3yr history. Capital turnover N/A, R&D intensity 520.2%. These pillars form the core of CytoMed Therapeutics Ltd's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (1.3/20) and margin superiority (2.5/20). ROE proxy -112.5% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect CytoMed Therapeutics Ltd's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include robust top-line growth of 172% expanding the revenue base. The margin cascade from -347% gross to -687% operating to -687.1% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 15th percentile.
The margin profile shows gross margins of -347%, operating margins of -687%, net margins of -687.1%. Return metrics include ROE of -112.5% and ROA of -100.2%. Relative to the Manufacturing sector, gross margins are 389.6 percentage points below the sector median of 43%, and ROE of -112.5% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 5%, revenue growth of 172%. The sector median D/E is 0%, putting CytoMed Therapeutics Ltd at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Below-average quality (15th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Elevated short interest (88th percentile) indicates that sophisticated market participants are betting against the stock.
SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre (“UMMC”
CytoMed Therapeutics has completed the acquisition of allogeneic gamma delta T cell technology from TC BioPharm, aiming to develop cancer treatments for China and India. The technology has completed a Phase I clinical trial and received FDA orphan drug designation for Acute Myeloid Leukemia.
Shares of The Container Store Group, Inc. (NYSE: TCS) shares fell sharply during Wednesday’s session following weak quarterly results. Container Store Group posted adjusted loss of 8 cents per share, compared to market expectations for a loss of 5 cents per share. The company’s quarterly sales came in at $214.90 million versus estimates of $220.72 million. Container Store Group shares dipped 22.7% to $1.3150 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 400% to $7.51. The company announced it planned to join the Communications Industry Association. HOLO intends to join the Communications Industry Association to foster information technology innovation. SMX (Security Matters) Public Limited Company (NASDAQ: SMX) shares climbed 138% to $0.5528. Glatfelter Corporation (NYSE: GLT) climbed 68.8% to $2.1450 after the company and Berry Global announced they entered into definitive agreements for Berry to spin-off and merge the majority of its Health, Hygiene and Specialties segment to include its Global Nonwovens and Films business with Glatfelter. MariaDB plc (NYSE: MRDB) gained 57% to $0.3782 after jumping more than 26% on Tuesday. ThermoGenesis Holdings, Inc. (NASDAQ: THMO) climbed 37.7% to $0.8101. Recon Technology, Ltd. (NASDAQ: RCON) rose 33.3% to $0.1934. Ault Alliance, Inc. (NYSE: AULT) surged 28.1% to $0.4549. Ault Alliance said it determined not to pursue new acquisitions during 2024, though it may continue to make strategic investments. Luokung Technology Corp. (NASDAQ: LKCO) gained 27.4% to $0.6269. MicroAlgo Inc. (NASDAQ: MLGO) rose 27% to $0.4939. Aviat Networks, Inc. (NASDAQ: AVNW) surged 23.7% to $37.20 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates. Jianpu Technology Inc. (NYSE: JT) gained 18.5% to $0.7584. Enphase Energy, Inc. (NASDAQ: ENPH) rose 17.7% to $118.36 after the company reported quarterly financial results. Sonos, Inc. ...
Upgrades For Vintage Wine Estates Inc (NASDAQ:VWE), Canaccord Genuity upgraded the previous rating of Sell to Hold. Vintage Wine Estates earned $0.11 in the second quarter, compared to $0.17 in the year-ago quarter. At the moment, the stock has a 52-week-high of $7.83 and a 52-week-low of $0.81. Vintage Wine Estates closed at $1.06 at the end of the last trading period. DA Davidson upgraded the previous rating for Harley-Davidson Inc (NYSE:HOG) from Neutral to Buy. Harley-Davidson earned $2.04 in the first quarter, compared to $1.45 in the year-ago quarter. At the moment, the stock has a 52-week-high of $51.77 and a 52-week-low of $30.85. Harley-Davidson closed at $36.60 at the end of the last trading period. BTIG upgraded the previous rating for Forestar Group Inc (NYSE:FOR) from Neutral to Buy. For the third quarter, Forestar Group had an EPS of $0.93, compared to year-ago quarter EPS of $0.80. At the moment, the stock has a 52-week-high of $25.99 and a 52-week-low of $10.28. Forestar Group closed at $25.28 at the end of the last trading period. According to B of A Securities, the prior rating for Consolidated Edison Inc (NYSE:ED) was changed from Neutral to Buy. In the first quarter, Consolidated Edison showed an EPS of $1.83, compared to $1.47 from the year-ago quarter. At the moment, the stock has a 52-week-high of $102.19 and a 52-week-low of $78.21. Consolidated Edison closed at $95.89 at the end of the last trading period. According to B of A Securities, the prior rating for Marsh & McLennan Companies Inc (NYSE:MMC) was changed from Underperform to Neutral. In the second quarter, Marsh & McLennan showed an EPS of $2.20, compared to $1.89 from the year-ago quarter. The current stock performance of Marsh & McLennan shows a 52-week-high of $190.92 and a 52-week-low of $148.11. Moreover, at the end of the last trading period, the closing price was at $189.20. Baird upgraded the previous rating for WNS (Holdings) Ltd (NYSE:WNS) from Neutral to Outperform. In the first quarter, WNS (Hldgs) showed an EPS of $1.01, compared to $0.90 from the year-ago quarter. At the moment, the stock has a 52-week-high of $94.96 and a 52-week-low of $67.34. WNS (Hldgs) closed at $68.43 at the end of the last trading period. For Abbott Laboratories (NYSE:ABT), Wolfe Research upgraded the previous rating of Underperform to Peer Perform. For the second quarter, Abbott Laboratories had an EPS of $1.08, compared to year-ago quarter EPS of $1.43. The stock has a 52-week-high of $115.69 and a 52-week-low of $93.29. At the end of the last trading period, Abbott Laboratories closed at $111.83. Piper Sandler upgraded the previous rating for SL Green Realty Corp (NYSE:SLG) from Neutral to Overweight. SL Green Realty earned $1.43 in the second quarter, compared to $1.87 in the year-ago quarter. The stock has a 52-week-high of $51.69 and a 52-week-low of $19.06. At the end of the last trading period, SL Green Realty closed at $33.61. See all analyst ratings upgrades. Downgrades For Sirius XM Holdings Inc (NASDAQ:SIRI), Seaport Global downgraded the previous rating of Neutral to Sell. For the first quarter, Sirius XM Holdings had an EPS of $0.06, compared to year-ago quarter EPS of $0.08. At the moment, the stock has a 52-week-high of $7.95 and a 52-week-low of $3.32. Sirius XM Holdings closed at $7.81 at the end of the last trading period. For The Timken Co (NYSE:TKR), B of A Securities downgraded the previous rating of Buy to Neutral. In the first quarter, Timken showed an EPS of $2.09, compared to $1.61 from the year-ago quarter. The current stock performance of Timken shows a 52-week-high of $95.08 and a 52-week-low of $57.59. Moreover, at the end of the last trading period, the closing price was at $93.07. Wells Fargo downgraded the previous rating for Equinix Inc (NASDAQ:EQIX) from Overweight to Equal-Weight. In the first quarter, Equinix showed an EPS of $8.59, compared to $7.16 from the year-ago quarter. The current stock performance of Equinix shows a 52-week-high of $816.22 and a 52-week-low of $495.11. Moreover, at the end of the last trading period, the closing price was at $810.51. According to Deutsche Bank, the prior rating for Sirius XM Holdings Inc (NASDAQ:SIRI) was changed from Buy to Sell. In the first quarter, Sirius XM Holdings showed an EPS of $0.06, compared to $0.08 from the year-ago quarter. The current stock performance of Sirius XM Holdings shows a 52-week-high of $7.95 and a 52-week-low of $3.32. Moreover, at the end of the last trading period, the closing price was at $7.81. For Blackstone Inc (NYSE:BX), JP Morgan downgraded the previous rating of Overweight to Neutral. In the second quarter, Blackstone showed an EPS of $0.93, compared to $1.49 from the year-ago quarter. At the moment, the stock has a 52-week-high of $110.87 and a 52-week-low of $71.73. Blackstone closed at $107.51 at the end of the last trading period. According to B of ...Full story available on Benzinga.com
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. Ault Alliance, Inc. (NYSE: AULT) gained 73.3% to $5.72 after the company said it anticipates $200 million in annual revenue for 2023. Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares climbed 67.3% to $11.34 after the company announced collaboration and a $50 million investment from NVIDIA. Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 45.1% to $2.5239 after gaining 15% on Tuesday. Liminal BioSciences Inc. (NASDAQ: LMNL) rose 39.6% to $8.31 after the company announced it entered into an arrangement agreement with Structured Alpha LP. Liminal minority shareholders are to receive $8.50 in cash per share in "go private" transaction. AVROBIO, Inc. (NASDAQ: AVRO) surged 38.8% to $1.36 after the company announced plans to explore strategic alternatives. LivePerson, Inc. (NASDAQ: LPSN) shares climbed 33.7% to $5.70 after the company announced a planned CEO transition. InspireMD, Inc. (NYSE: NSPR) gained 31% to $3.03. Daktronics, Inc. (NASDAQ: DAKT) rose 30.4% to $7.97 following better-than-expected fourth-quarter results. Freeline Therapeutics Holdings plc (NASDAQ: FRLN) shares jumped 28.7% to $4.7759. Society Pass Incorporated (NASDAQ: SOPA) gained 23.6% to $0.7490. Ascendiant Capital recently initiated coverage on Society Pass with a Buy rating and announced a price target of $3.5. Holley Inc. (NYSE: HLLY) surged 21.6% to $5.35 on positive analyst changes. B of A Securities upgraded the stock and raised its price target from $3.25 to $6, and JP Morgan upgraded the stock from Overweight to Neutral and announced a $7 price ...
Above 50MA
37.18%
Net New Highs
+51081